- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06096779
En studie som evaluerer atezolizumab, med eller uten bevacizumab, hos pasienter med ikke-opererbart hepatocellulært karsinom og Child-Pugh B7 og B8 skrumplever (Kirros)
En fase II, åpen etikett, multi-kohort, multisenterstudie i pasienter med ikke-opererbart hepatocellulært karsinom og Child-Pugh B7 og B8 cirrhosis
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a Phase II, open-label, multicohort, multicenter study in participants with unresectable, locally advanced, or metastatic HCC who have Child-pugh B7 or B8 liver cirrhosis and have received no prior systemic therapy in this treatment setting. The study is designed to non-comparatively evaluate the safety of atezolizumab plus bevacizumab (Cohort A) or atezolizumab monotherapy (Cohort B) in this population.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Arizona
-
Tucson, Arizona, Forente stater, 85724
- University of Arizona Cancer Center
-
-
California
-
La Jolla, California, Forente stater, 92093
- UC San Diego Moores Cancer Center
-
Los Angeles, California, Forente stater, 90089-5601
- University of Southern California-Keck School of Medicine -1975 Zonal Ave
-
Newport Beach, California, Forente stater, 92663
- University of Southern California
-
Orange, California, Forente stater, 92868
- University of California Irvine Medical Center
-
Pasadena, California, Forente stater, 91105-2561
- California Liver Research Institute
-
Sacramento, California, Forente stater, 95817
- University of California Davis Medical Center
-
Stanford, California, Forente stater, 94305
- Stanford Health Care
-
Torrance, California, Forente stater, 90502-2006
- Harbor UCLA Medical Center
-
West Hollywood, California, Forente stater, 90048-2422
- Cedars Sinai Comprehensive Transplant Center
-
-
Connecticut
-
Hartford, Connecticut, Forente stater, 06106
- Hartford Healthcare Cancer Institute at Hartford Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20037
- George Washington University- Medical Faculty Associates
-
Washington D.C., District of Columbia, Forente stater, 20422-0001
- Washington DC VA Medical Center
-
-
Florida
-
Orlando, Florida, Forente stater, 32806
- Orlando Health Inc.
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611-2908
- Northwestern University
-
Chicago, Illinois, Forente stater, 60612-4795
- University of Illinois Health Outpatient Care Center
-
Chicago, Illinois, Forente stater, 60637-1426
- The Duchossois Center for Advanced Medicine
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40536-7001
- University of Kentucky - Markey Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater, 70805
- LSU Health Baton Rouge
-
Baton Rouge, Louisiana, Forente stater, 70808-4300
- Our Lady of the Lake Cancer Institute
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Forente stater, 02111
- Tufts Medical Center
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48201
- Barbara Ann Karmanos Cancer Institute
-
Detroit, Michigan, Forente stater, 48202
- Henry Ford Health System
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64111
- Saint Luke?s Hospital of Kansas City
-
-
New Jersey
-
New Brunswick, New Jersey, Forente stater, 08901
- Rutgers Cancer Institute of New Jersey
-
Newark, New Jersey, Forente stater, 07103
- Rutgers Cancer Institute of New Jersey at University Hospital
-
-
New York
-
Mineola, New York, Forente stater, 11501-4064
- NYU Langone Hospital - Long Island
-
New York, New York, Forente stater, 10029
- Icahn School of Medicine at Mount Sinai
-
The Bronx, New York, Forente stater, 10467
- Montefiore Medical Center
-
The Bronx, New York, Forente stater, 10468-3904
- James J Peters Veterans Administration Medical Center - NAVREF
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28204
- Levine Cancer Institute
-
-
Ohio
-
Dayton, Ohio, Forente stater, 45428-9000
- Dayton VA Medical Center - NAVREF - PPDS
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104-5020
- The University of Oklahoma Health Sciences Center
-
-
Oregon
-
Hillsboro, Oregon, Forente stater, 97124-5806
- Kaiser Permanente Westside Medical Center
-
Portland, Oregon, Forente stater, 97239-3011
- OHSU Knight Cancer Institute Hematology Oncology
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Jefferson Health Honickman Center
-
Pittsburgh, Pennsylvania, Forente stater, 15240
- Veterans Affairs Pittsburgh Healthcare System - NAVREF - PPDS
-
-
Tennessee
-
Germantown, Tennessee, Forente stater, 38138-1762
- The West Clinic (East Campus)
-
Nashville, Tennessee, Forente stater, 37208-2918
- Nashville General Hospital at Meharry
-
-
Texas
-
Dallas, Texas, Forente stater, 75390-0001
- University of Texas Southwestern Medical Center
-
Dallas, Texas, Forente stater, 75246-2008
- Texas Oncology (Worth) - USOR
-
Dallas, Texas, Forente stater, 75203-1260
- Liver Institute at Methodist Dallas
-
Dallas, Texas, Forente stater, 75235
- Moody Outpatient Center ? Parkland Health
-
Denison, Texas, Forente stater, 75020-0084
- Texas Oncology - Denison Cancer Center
-
Houston, Texas, Forente stater, 77025-1669
- Kelsey Research Foundation
-
Houston, Texas, Forente stater, 77030-4211
- Michael E Debakey VA Medical Center - NAVREF - PPDS
-
-
Utah
-
Murray, Utah, Forente stater, 84107-5741
- Intermountain Healthcare
-
St. George, Utah, Forente stater, 84790
- Intermountain Cancer Center
-
-
Virginia
-
Falls Church, Virginia, Forente stater, 22042
- Inova Schar Cancer Institute
-
Richmond, Virginia, Forente stater, 23226-1925
- Bon Secours St. Mary's Hospital
-
Richmond, Virginia, Forente stater, 23298-5028
- VCU Medical Center North Hospital
-
-
Washington
-
Seattle, Washington, Forente stater, 98101
- Virginia Mason Medical Center
-
-
-
-
-
Rio Piedras, Puerto Rico, 00935
- Pan American Center for Oncology Trials, LLC
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
General Inclusion Criteria:
- Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants
- Disease that is not amenable to curative surgical and/or locoregional therapies
- No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and/or unresectable HCC
- Measurable disease (at least one untreated target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 7 days prior to initiation of study treatment
- Child-pugh B7 or B8 cirrhosis at screening and within 7 days prior to study treatment
- Adequate hematologic and end-organ function
- Life expectancy of at least 12 weeks
- Female participants of childbearing potential must be willing to avoid pregnancy and egg donation
- Absolute neutrophil count (ANC) ≥1.0 x 10^9 per liter (/L) (≥1000 per microliter [/μL]) without granulocyte colony-stimulating factor support
- Platelet count ≥ 50 × 109/L (50,000/μL) without transfusion
- Hemoglobin (Hb) ≥ 80 grams per liter (g/L) (8 grams per deciliter [g/dL])
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × upper limit of normal (ULN)
- Serum bilirubin ≤ 3 × ULN
- Creatinine clearance ≥ 50 milliliters per minute (mL/min) (calculated using the Cockcroft-gault formula)
- Serum albumin ≥ 20 g/L (2.0 g/dL) without transfusion in the prior 3 months
- International normalized ratio (INR) ≤2.3
General Exclusion Criteria:
- Pregnancy or breastfeeding
- Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
- Treatment with investigational therapy within 28 days prior to initiation of study treatment
- Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure
- Treatment with systemic immunostimulatory agents
- Treatment with systemic immunosuppressive medication
- Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment
- Inadequately controlled hypertension
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Participants who have a known concurrent malignancy that is progressing or requires active treatment, who have not completely recovered from treatment, or who have a significant malignancy history that, in the opinion of the investigator, should preclude participation
- Participants on preventative hormonal therapies (i.e., tamoxifen and other hormonal inhibitors) are not excluded
- Known fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- Prior allogeneic stem cell or solid organ transplantation
- Actively listed for liver transplantation
- Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)
- Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding
- A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment
- Grade ≥3 hemorrhage or bleeding event within 6 months prior to initiation of study treatment
- Hepatic encephalopathy is allowed if no active symptoms or stable within 3 months of study treatment
- History, planned, or recommended placement of transjugular intrahepatic portosystemic shunt (TIPS) is excluded from Cohort A only. TIPS is acceptable in Cohort B
- Diagnostic paracentesis is allowed. Therapeutic paracentesis: one large volume paracentesis prior to enrollment with diuretic controlled ascites is allowed.
- Participants with ascites controlled on diuretics are allowed
- History of spontaneous bacterial peritonitis within last 12 months
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Cohort A: Atezolizumab+Bevacizumab
Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator. |
Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
Andre navn:
Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) by IV infusion on Day 1 of each 21-day cycle.
Andre navn:
|
|
Eksperimentell: Cohort B: Atezolizumab
Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator. |
Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants With Adverse Events (AEs)
Tidsramme: Baseline through the end of the study (up to approximately 36 months)
|
An AE is any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Severity is determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0) in Cohorts A and B. |
Baseline through the end of the study (up to approximately 36 months)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Clinical Trials, Hoffmann-La Roche
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Neoplasmer etter nettsted
- Neoplasmer
- Neoplasmer etter histologisk type
- Sykdommer i fordøyelsessystemet
- Neoplasmer, kjertel og epitel
- Adenokarsinom
- Karsinom
- Patologiske tilstander, tegn og symptomer
- Karsinom, hepatocellulært
- Neoplasmer i leveren
- Fibrose
- Leversykdommer
- Fettlever
- Neoplasmer i fordøyelsessystemet
- Aminosyrer, peptider og proteiner
- Proteiner
- Antistoffer, monoklonalt, humanisert
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Bevacizumab
- Atezolizumab
Andre studie-ID-numre
- ML44719
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .